Investigators aim to establish an optimal dose and explore CER-1236's safety and preliminary anti-tumor activity.

If approved, ziftomenib could be the first FDA-approved Menin inhibitor for relapsed/refractory acute myeloid leukemia with ...

Scientists at the San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), Milan, have found that gene editing using ...

The FDA set a PDUFA date in late 2025 as ziftomenib led to significant disease response in patients with common subtype of ...

Redwire Corporation (NYSE: RDW), a leader in space infrastructure for the next generation space economy, announced today that it has been awarded a contract from Aspera Biomedicines, Inc. (Aspera), a ...

A 13-year-old boy who returned to football for the first time since a stem-cell transplant has scored the winner to save his ...

CR/CRh rate of 23% in pivotal Ph 2 cohort of R/R NPM1-m AML patients - - Consistent efficacy with comparable CR/CRh rates and clinically meaningful MRD-negative responses across ...